Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Month of March 2026
Date Filed: March 13, 2026
Principal Executive Office: Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. As a development stage enterprise, the document focuses on corporate governance and regulatory updates rather than financial performance data.
Material Changes
No material changes to financial position or operations are detailed in this specific filing. The primary update is the submission of an exhibit regarding a new facility.
Guidance, Outlook, and Material Events
- Material Event: Submission of Exhibit 99.1 titled "ATH - Unmarketable Parcel Sale Facility."
- Regulatory Action: This Form 6-K is being incorporated by reference into Registration Statements on Form S-8 (Files No. 333-251073, 333-248980, 333-228671) and Form F-3 (Files No. 333-274816, 333-251647, 333-231417, 333-250076).
- Management Commentary: No specific outlook or commentary on business strategy is provided in this text.
Investor Verification Checklist
- Review the full text of Exhibit 99.1 ("Unmarketable Parcel Sale Facility") to understand the terms and potential dilution or capital impact.
- Verify the status of the referenced Form S-8 and Form F-3 registration statements for details on share issuance.
- Confirm the company's current cash runway and burn rate, as this filing does not disclose financial metrics.